Relevant bibliographies by topics / 177Lu

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic '177Lu'

Author: Grafiati
Published: 4 June 2021
Last updated: 19 June 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic '177Lu.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "177Lu"

1

Дьячков, А. Б., А. А. Горкунов, А. В. Лабозин та ін. "Исследование кинетических параметров схемы лазерной фотоионизации лютеция". Журнал технической физики 128, № 3 (2020): 301. http://dx.doi.org/10.21883/os.2020.03.49055.277-19.

Full text
Abstract:
Разработка лазерного фотоионизационного метода получения радионуклида 177Lu для применения в медицине требует знания интенсивностей светового насыщения по каждой ступени схемы фотоионизации лютеция (5d6s2 2D3/2-5d6s6p 4Fo5/2-5d6s7s 4D3/2-(53375 сm-1)o1/2) с учетом используемых компонент сверхтонкой структуры переходов. В работе экспериментально определены эффективные сечения возбуждения различных сверхтонких компонент переходов для изотопов 175Lu, 176Lu, 177Lu и 177mLu излучением импульсных перестраиваемых по длине волны лазеров на красителях, накачиваемых лазерами на парах меди. Ключевые слова: лазерная фотоионизация, сверхтонкая структура, 177Lu, лазерное разделение изотопов.
APA, Harvard, Vancouver, ISO, and other styles
2

Riskiana, Dewi Nur, Mukhtar Effendi, Ariyawan Sunardi, Mochamad Imron, and Abdul Aziz Rohman Hakim. "PERHITUNGAN PRODUKSI 177Lu BERDASARKAN VARIASI WAKTU IRADIASI DI REAKTOR RSG-GAS MENGGUNAKAN PROGRAM ORIGEN 2.1." Reaktor : Buletin Pengelolaan Reaktor Nuklir 18, no. 1 (2021): 27. http://dx.doi.org/10.17146/bprn.2021.18.1.6281.

Full text
Abstract:
Telah dilakukan perhitungan radioaktivitas 177Lu (Lutetium-177) dengan variasi waktu iradiasi di Reaktor RSG-GAS. 177Lu merupakan radioisotop golongan lantanida yang sekarang banyak digunakan sebagai agen radioterapi kanker. Perhitungan ini menggunakan paket program ORIGEN 2.1 dengan memasukkan data inputan seperti fluks neutron (1 x 104 n/m2 s), massa lutetium oksida (3 miligram) dan lama iradiasi (4 hari,8 hari, dan 12 hari). Dalam penentuan massa lutetium dibedakan menjadi dua komponen yaitu massa 176Lu dan 175Lu yang berturut-turut sebesar 2 miligram dan 0,6 miligram. Perhitungan tersebut menghasilkan radioaktivitas produksi 177Lu tertinggi sebesar 30,939 GBq pada 12 hari iradiasi. Sedangkan, radioaktivitas produksi 177Lu terendah sebesar 15,939 GBq pada 4 hari iradiasi. Dari hasil tersebut, radioaktivitas produksi 177Lu dengan lama iradiasi mempunyai hubungan lininer. Kemudian radioaktivitas produksi 177Lu untuk melebihi 20 GBq dapat dimulai dari 8 hari iradiasi. Adapun radioaktivitas peluruhan 177Lu dengan waktu peluruhannya memiliki hubungan yang berbanding terbalik.
APA, Harvard, Vancouver, ISO, and other styles
3

Gurin, Andrey, Yelena Chakrova, Ilona Matveyeva, and Patrick Riss. "Optimization of Reaction Parameters for the Synthesis of 177Lu-DOTAELA." Revista de Chimie 71, no. 8 (2020): 55–62. http://dx.doi.org/10.37358/rc.20.8.8278.

Full text
Abstract:
The article provides a comparison of the theoretically calculated and experimentally determined yield of the reaction 176Lu (n, �A)177Lu. Also, it provides the results of the studies on lutetium-177 labeling of a non-peptide antagonist of gonadotropin-releasing hormone (GnRH) elagolix (ELA) associated with a chelating DOTA (DOTAELA). The synthesized DOTAELA complex was labeled with the 177Lu isotope.177Lu was produced by the reaction (n, �A) using the enriched LuCl3 target at the reactor WWR�CK. Production of 177Lu by the (n, �A) reaction from the enriched 176Lu target achieved by irradiation for 17 days. All stages of the complex preparation were evaluated by paper chromatography. The optimal technological parameters for the synthesis of the complex 177Lu-DOTAELA are: pH - 4.5, 90-100 �aC and 40 min. The obtained optimal parameters made it possible to produce a labeled complex of 177Lu�CDOTAELA with a radiochemical yield of �Y 95%.
APA, Harvard, Vancouver, ISO, and other styles
4

Nguyen, Ngoc Tuan, Van Dong Duong, Van Cuong Bui, Thanh Minh Pham, and Thi Hang Nguyen. "Study on the production of ¹⁷⁷Lu for medical purposes at the Dalat Research Reactor. Part 1. Study on production of ¹⁷⁷Lu at the Dalat Research Reactor." Nuclear Science and Technology 5, no. 1 (2015): 18–25. http://dx.doi.org/10.53747/jnst.v5i1.181.

Full text
Abstract:
Lutetium-177 (177Lu) radioisotope used for medical purposes has been produced at the Dalat Nuclear Research Reactor during 2012-2014. The product was synthezed by the activation reaction 176Lu (n,γ) 177Lu. The target was Lutetium oxide with an abundance of 176Lu being 2.59% and the irradiation was conducted with a neutron flux of 2.1013 n cm-2 s-1. The activity of the 177Lu product was 39,59 Ci g-1 after 108 hous of the irradiation. The yield of this method was much higher compared to those of the reaction 176Yb(n, γ)177Yb → 177Lu + β- which for the same time could be 15mCi/50mg only. Because of low specific radioactivity the preparation of 177Lu made from the activation of 176Yb cannot be applied for the medical purposes. Additionally, the separation yield of 177Lu from 177Yb is rather low, it is usualy of approximately 70%.
APA, Harvard, Vancouver, ISO, and other styles
5

Widyaningrum, Triani, Mr Triyanto, Endang Sarmini, Umi Nur Sholikhah, and Sunarhadijoso Soenarjo. "KARAKTERISTIK PEMISAHAN RADIOLUTESIUM-177/177mLu DAN RADIOITERBIUM-169/175Yb PADA KOLOM RESIN LN-EICHROM." Jurnal Sains dan Teknologi Nuklir Indonesia 16, no. 1 (2015): 1. http://dx.doi.org/10.17146/jstni.2015.16.1.2353.

Full text
Abstract:
ABSTRAK KARAKTERISTIK PEMISAHAN RADIOLUTESIUM- 177/177mLu DAN RADIOITERBIUM-169/175Yb PADA KOLOM RESIN LN-EICHROM. Radiolutesium-177Lu keradioaktifan jenis tinggi merupakan salah satu radiolantanida yang banyak digunakan untuk menangani berbagai kasus kanker, namun di Indonesia penggunaan radiofarmaka bertanda 177Lu belum dapat dijanjikan karena teknik produksi radioisotop primernya belum dikuasai. Prospek produksi 177Lu melalui reaksi inti 176Yb (n,g) 177Yb* à 177Lu* + β– dipelajari melalui metode pemisahan matrik 177/177mLu-169/175Yb/176Yb dalam sistem kromatografi kolom resin LN-Eichrom. Profil fraksinasi dan karakteristik pemisahan dipelajari dengan pemeriksaan keradioaktifan dan analisis spektro-metri-g terhadap hasil elusi larutan sasaran pasca iradiasi. Bahan sasaran digunakan 176Yb2O3 alam dan 176Lu2O3 diperkaya. Hasil penelitian menunjukkan bahwa radiolutesium-177/177mLu dapat dipisahkan dari matrik radioiterbium-169/175Yb/natYb melalui sistem kromatografi kolom dengan fase diam resin LN-Eichrom dan fase gerak larutan HNO3, dengan konsentrasi antara 1,5 – 4 M untuk mendapatkan pemisahan yang efektif, selektif dan kuantitatif. Reaksi inti 176Yb(n,g) 177Yb* à 177Lu + β– merupakan model reaksi inti yang perlu dipertimbangkan walau-pun harus melibatkan tahapan pemisahan produk 177Lu dari matrik sasaran Yb pasca iradiasi. Prosedur pemisahan yang dilakukan masih perlu diperbaiki melalui pemilihan jenis dan konsentrasi fase gerak pengelusi yang lebih tepat. ABSTRACT SEPARATION CHARACTERISTIC OF RADIOLUTETIUM-177/177mLu AND RADIOY-TTERBIUM-169/175Yb ON LN-EICHROM RESIN COLUMN. High specific activity radiolutetium-177Lu is one of radiolanthanides that is widely used to handle variety of cancer cases, but in Indonesia the use of 177Lu-labeled-radiopharmaceutical can not be promised yet as the primary radioisotope production techniques have not been mastered. The prospect of 177Lu production based on the nuclear reaction of 176Yb (n,g) 177Yb * ® 177Lu * + β– in the BATAN’s G.A. Siwabessy reactor was learned through the separation characteristics of 177/177mLu-169/175Yb /176Yb process matrices in the LN-Eichrom resin column chromatography. The separation and fractionation profiles were characterized by radioactivity measurement as well as g-spectrometric analysis of the eluting post-irradiated target solution. The target materials used were natural 176Yb2O3 and enriched 176Lu2O3. The results showed that radiolutetium-177/177mLu can be separated from the radioiterbium-169/175Yb/natYb matrix by column chromatography system with a stationary phase of LN-Eichrom resin using HNO3 solution as the mobile phase, but the concentration of HNO3 used is a critical variable, between 1.5 - 4 M, to obtain an effective separation selectively and quantitatively. The nuclear reaction of 176Yb (n,g) 177Yb* ® 177Lu + β– using natural Yb2O3 is considered to be better, although it must involve 177Lu product separation stage from the post-irradiated natural Yb target matrix. The presented separation procedure still needs to be improved through the selection of the type and the concentration of the mobile phase used to gain more appropriate elution solvent.
APA, Harvard, Vancouver, ISO, and other styles
6

Rosmayani, Lena, Anis Rohanda, and Raden Farzand Abdullatif. "A SIMULATION OF IRRADIATION CALCULATIONS ON LUTETIUM-177 PRODUCTION IN RSG-GAS USING U3SI2-AL AND U9MO-AL FUELS." JURNAL TEKNOLOGI REAKTOR NUKLIR TRI DASA MEGA 25, no. 2 (2023): 45. http://dx.doi.org/10.55981/tdm.2023.6793.

Full text
Abstract:
This research is a simulation of irradiation calculations on the production of the radioisotope Lutetium-177 (177Lu) in the G.A Siwabessy Reactor (RSG-GAS). This study aims to analyze the comparative calculation of 177Lu activity and its purity. One of the production methods of 177Lu in RSG-GAS is carried out by irradiating Lu2O3 targets. This Lu2O3 target irradiation produced the radioisotope 177Lu along with 177mLu as an impurity. For Medical treatment using radioisotopes, the minimum activity for 177Lu is 20 GBq/mg, and the impurity should not exceed 0.1%. Calculations were carried out with thermal neutron flux input at 15 MWt operational power for the RSG-GAS core with U3Si2-Al fuel (density 2.96 gU/cc and 3.55 gU/cc) and U9Mo-Al fuel (density 3.55 gU/cc). Calculations were carried out by simulating 8 days of irradiation using ORIGEN2.1. The results showed that the 177Lu activity resulting from irradiation of Lu2O3 targets at various CIP positions in the U9Mo-Al reactor core was larger than that of the U3Si2-Al core. Until the 30th day, the 177Lu product resulting from irradiation on the U3Si2-Al and U9Mo-Al cores still meets the minimum value of 20 GBq/mg for treatment needs in nuclear medicine, with the activity value of 177Lu resulting from irradiation on the U3Si2-Al core ranging from 241-403 GBq/mg, while the activity of irradiated 177Lu in the U9Mo-Al core ranges from 335-561 GBq/mg. In addition, until the 30th day of decay, 177Lu has a percentage value of 177mLu irradiated in the U9Mo-Al and U3Si2-Al cores of 0.0346% and 0.0344%, respectively. The results are still below the maximum impurity value of 0.1% and thus safe to use as a therapeutic agent. Keywords: 177Lu, Activity, RSG-GAS, ORIGEN2, Irradiation
APA, Harvard, Vancouver, ISO, and other styles
7

Kazakov, Andrey G., Taisya Y. Ekatova, Julia S. Babenya, et al. "Recovery of 177Lu from Irradiated HfO2 Targets for Nuclear Medicine Purposes." Molecules 27, no. 10 (2022): 3179. http://dx.doi.org/10.3390/molecules27103179.

Full text
Abstract:
A new method of production of one of the most widely used isotopes in nuclear medicine, 177Lu, with high chemical purity was developed; this method includes irradiation of the HfO2 target with bremsstrahlung photons. The irradiated target was dissolved in HF and then diluted and placed onto a column filled with LN resin. Quantitative sorption of 177Lu could be observed during this process. The column later was rinsed with the mixture of 0.1 M HF and 1 M HNO3 and then 2 M HNO3 to remove impurities. Quantitative desorption of 177Lu was achieved by using 6 M HNO3. The developed method of 177Lu production ensures high purification of this isotope from macroquantities of hafnium and zirconium and radioactive impurities of carrier-free yttrium. The content of 177mLu in 177Lu in photonuclear production was determined. Due to high chemical and radionuclide purity, 177Lu obtained by the developed method can be used in nuclear medicine.
APA, Harvard, Vancouver, ISO, and other styles
8

Дьячков, А. Б., А. А. Горкунов, А. В. Лабозин та ін. "Исследование схемы селективной фотоионизации -=SUP=-177-=/SUP=-Lu". Журнал технической физики 126, № 2 (2019): 103. http://dx.doi.org/10.21883/os.2019.02.47189.212-18.

Full text
Abstract:
AbstractThe hyperfine structure of transitions in the three-step scheme 5 d 6 s ^22 D _3/2–5 d 6 s 6 p ^4 F $$_{{5/2}}^{^\circ }$$ –5 d 6 s 7 s ^4 D _3/2– (53 375 cm^–1) $$_{{1/2}}^{^\circ }$$ of lutetium ionization is studied for ^175Lu, ^176Lu, and ^177Lu isotopes using the photoionization laser spectroscopy method. Values of the magnetic dipole ( A ) and electric quadrupole ( B ) interaction constants are determined, as well as the energies, the isotope shifts, and the radiative lifetimes for the 5 d 6 s 7 s ^4 D _3/2 and (53 375 cm^–1) $$_{{1/2}}^{^\circ }$$ levels.
APA, Harvard, Vancouver, ISO, and other styles
9

Bhardwaj, Rupali, Hubert T. Wolterbeek, Antonia G. Denkova, and Pablo Serra-Crespo. "Modelling of the 177mLu/177Lu radionuclide generator." Applied Radiation and Isotopes 166 (December 2020): 109261. http://dx.doi.org/10.1016/j.apradiso.2020.109261.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Mizukoshi, Yoshihide, Shota Tsuchida, Hiroko Inaba, et al. "Abstract 6024: A novel carbonic anhydrase IX targeting radiopeptide, 64Cu-PD-32766 and 177Lu-PD-32766, exhibit promising theranostic potential in ccRCC tumors." Cancer Research 84, no. 6_Supplement (2024): 6024. http://dx.doi.org/10.1158/1538-7445.am2024-6024.

Full text
Abstract:
Abstract Introduction: Carbonic Anhydrase IX (CA9) is a zinc metalloenzyme that regulates the pH for cell growth. CA9 is considered an attractive target and is upregulated in a variety of cancers, especially, in 95% of clear cell renal cell carcinoma (ccRCC) where there remains a large clinical unmet need despite the availability of several newly approved medicines. PeptiDream has identified PD-32766, a novel macrocyclic peptide, targeting CA9 and can be labeled with radionuclides such as copper (64Cu) and lutetium (177Lu), which enables tumor-specific PET bioimaging and radiotherapy. Here we report the theranostic translational feasibility of PD-32766 for ccRCC. Materials and Methods: PD-32766 was discovered using Peptide Discovery Platform System (PDPS), a proprietary screening system of PeptiDream. Binding affinity of PD-32766, 63Cu-PD-32766 and 175Lu-PD-32766 to CA9 was measured by SPR. For in vivo evaluation, we used a xenograft model in which VMRC-RCW (ccRCC cell line with similar CA9 expression level to clinical samples) was subcutaneously transplanted into nude mice. To assess biodistribution, 64Cu-PD-32766 or 177Lu-PD-32766 was dosed to VMRC-RCW xenograft mice, and the percentage of injected dose in tumors and major organs was quantified by cut and count method. To evaluate whether PET imaging can detect tumors, 64Cu-PD-32766 was dosed to VMRC-RCW xenograft mice and after dosing, PET scanning was performed. For therapeutic experiments, 177Lu-PD-32766 was dosed to VMRC-RCW xenograft mice and tumor volume was measured for 45 days after dosing. Results: SPR analysis revealed that PD-32766, 63Cu-PD-32766 and 175Lu-PD-32766 exhibits an affinity of less than 0.2 nM for CA9. In in vivo biodistribution experiment, 64Cu-PD-32766 and 177Lu-PD-32766 showed specific and strong accumulation in tumors 4 hours after dosing (88 and 107% ID/g, for 64Cu-PD-32766 and 177Lu-PD-32766, respectively) and were highly retained in the tumors at 48 hours after dosing (37 and 51% ID/g, for 64Cu-PD-32766 and 177Lu-PD-32766, respectively). Maximal intensity in other normal tissues were 23 and 9 %ID/g (tumor/kidney=3.8 and 11.9 for 64Cu-PD-32766 and 177Lu-PD-32766, respectively at 4 hrs.). PET bioimaging of 64Cu-PD-32766 clearly detected only tumors, consistent with the biodistribution data. In therapeutic experiments, 177Lu-PD-32766 (30 MBq/mouse single or QW x3) was well tolerated and strikingly improved mouse survival compared with control animals for 45 days after transplantation, which suggests a robust tumor growth inhibition of 177Lu-PD-32766 dosing. Taken together, PD-32766 showed specific tumor accumulation and strong therapeutic effect in a clinically relevant xenograft model of ccRCC. Conclusion: PD-32766 has preferable properties for imaging and therapy with radionuclides and a great potential for theranostic use in ccRCC. Citation Format: Yoshihide Mizukoshi, Shota Tsuchida, Hiroko Inaba, Tatsuro Kotake, Takanori Aoki, Kai Orihara, Yuichi Funase, Naoki Kanazawa, Hikaru Shimizu, Kaita Sawano, Kentaro Suzuki, Hayato Yanagida, Takeru Ehara, Hidetomo Kitamura, Satoshi Matsushima, Masato Murakami. A novel carbonic anhydrase IX targeting radiopeptide, 64Cu-PD-32766 and 177Lu-PD-32766, exhibit promising theranostic potential in ccRCC tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6024.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "177Lu"

1

Sandström, Mattias. "Dosimetry of Radionuclide Therapy with 177Lu-octreotate." Doctoral thesis, Uppsala universitet, Avdelningen för sjukhusfysik, 2011. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-158973.

Full text
Abstract:
In radionuclide therapy it is still common to administer standard activities or to scale administered activity with blunt parameters such as body weight or surface area. This is not ideal because, due to considerable variation in kinetics, large safety margins have to be applied to avoid radiation damage to healthy organs, which causes under-treatment of many patients. To base the administered activity on individual dosimetry, as in other therapy modalities using ionizing radiation, will essentially solve this problem. However, dosimetry in radionuclide therapy is resource-demanding and debilitating for the patient because it involves a number of measurements to determine the kinetics of the therapy radionuclide and needs to be optimized for clinical feasibility. First, the ability to measure radioactivity distributions of radionuclides for therapy was investigated. SPECT measurements of 177Lu, which was later used clinically, showed good spatial resolution and a reasonable quantitative accuracy. A new method to calculate absorbed dose to solid risk organs and tumours was developed and applied in the clinic. Kinetic data were obtained by repeated SPECT measurements. Radiation concentration determined in small volumes of interest could then be multiplied by a constant to obtain absorbed dose because it was shown that cross-fire was negligible in organs with high activity concentration. The new dosimetry method, compared to other methods, was found to give better results with less effort. In addition, a method to calculate absorbed dose to bone marrow was developed and clinically implemented. In 200 patients, individual kinetics and absorbed dose were studied and variations were found to be large. Kidney was the dose-limiting organ in almost all patients (98.5%). Keeping the kidney dose < 23Gy, about half of the patients could receive 5, or up to 10 treatments instead of the stipulated 4.
APA, Harvard, Vancouver, ISO, and other styles
2

Gaudin, Émilie Odette. "Imagerie TEM/TDM quantitative du 99mTc- et du 177Lu." Master's thesis, Université Laval, 2015. http://hdl.handle.net/20.500.11794/26094.

Full text
Abstract:
Grâce à l’implémentation d’algorithmes de reconstruction 3D dans les systèmes d’imagerie TEM/TDM, une étude quantitative à partir des images reconstruites est possible. La quantification d’images TEM/TDM est nécessaire afin de permettre une étude dosimétrique 3D des patients atteints de tumeurs neuroendocrines traités au 177Lu-octréotate. Cependant, afin de permettre une quantification précise des images obtenues, plusieurs paramètres du système doivent être déterminés afin d’appliquer les corrections nécessaires. Dans le cadre de cette étude, l’appareil TEM/TDM utilisé est tout d’abord calibré. Pour ce faire, la stabilité temporelle, la sensibilité, le temps mort et l’effet de volume partiel de l’appareil sont déterminés pour différents radioisotopes. Par la suite, une étude comparative de deux plateformes de reconstruction est effectuée afin de trouver la technique offrant la plus haute précision quantitative d’images TEM/TDM. La calibration et l’étude des reconstructions de l’appareil TEM/TDM a permis de déterminer la procédure optimale pour l’imagerie quantitative du 177Lu et de 99mTc avec une erreur maximale de 3%. Ces résultats pourraient être validés à l’aide de données cliniques.
APA, Harvard, Vancouver, ISO, and other styles
3

Silva, Ana Claudia Machado. "Cinética e dosimetria do [177Lu-DOTA0, Tyr3]octreotato em pacientes com tumores carcinoides." Universidade de São Paulo, 2014. http://www.teses.usp.br/teses/disponiveis/85/85131/tde-29102014-130657/.

Full text
Abstract:
Tumores carcinoides (neoplasias bem diferenciadas) são tumores neuroendócrinos que podem surgir em diferentes locais anatômicos. Na população a prevalência dos tumores carcinoides é de aproximadamente 10 casos para um milhão de habitantes e sua incidência é maior na quinta e sexta década de vida. Este trabalho propõe um modelo cinético baseado na teoria da análise compartimental em humanos com tumores carcinoides que se submeterão ao tratamento com o radiofármaco [177Lu-DOTA0,Tyr3]Octreotato. Imagens cintilográficas dinâmicas planares, obtidas imediatamente à injeção de 370 MBq (10 mCi) do radiofármaco, foram obtidas com o tomógrafo SPECT (Single Photon Emission Computed Tomography). Por meio da seleção de regiões de interesse (ROI) os resultados foram digitalizados e aplicados ao modelo cinético aqui proposto. A primeira fase do estudo (atividade de 370 MBq) teve como objetivo conhecer os parâmetros cinéticos e subsequentemente, o paciente foi submetido ao protocolo de tratamento radioterápico, a critério médico, aos quatro ciclos de 7,4 GBq (200 mCi) do radiofármaco. Desta forma, foi possível estimar previamente as constantes cinéticas ki,j da biodistribuição do 177Lu-DOTATATO no corpo, sendo ki,j a fração de transferência do i-ésimo compartimento (tecido ou órgão) para o j-ésimo compartimento a partir das ROI demarcadoras dos órgãos de maior captação, a saber: fígado, rins, região vascularizada e tumores carcinoides. A partir das constantes cinéticas ki,j a estimativa de dose absorvida em 26 órgãos foi estimada pelo método MIRD. Os resultados dosimétricos foram compatíveis com outras metodologias descritas na literatura. Para um paciente adulto de 73,6 kg, em termos médios seus rins (sem os protetores renais) recebem a maior intensidade de dose (2,39 mGy/MBq) seguido do fígado (0,70 mGy/MBq). Observou-se que tumores com aproximadamente 100g recebem dose da ordem de 0,52 mGy/MBq independentemente da posição a que se encontram no corpo. Este achado se deve à predominância do dano devido às partículas beta quando comparado à radiação gama que possui pouco rendimento de emissão no processo de decaimento do 177Lu. Portanto, os parâmetros cinéticos que promovem a captação do 177Lu nas células são os principais responsáveis pela composição da dose no tumor e demais órgãos.<br>Carcinoid tumors (well differentiated neoplasms) are neuroendocrine tumors that may arise in different anatomical locations. The population prevalence of carcinoid tumors is approximately 10 cases per one million inhabitants. Its incidence is higher in the fifth and sixth decade of life. This paper proposes a kinetic model in humans with carcinoid tumors who will underwent treatment with the radiopharmaceutical [177Lu-DOTA0,Tyr3 ]OCTREOTATE based on the theory of compartmental analysis. Dynamic planar scintigraphic images acquired immediately upon injection of 370 MBq (10 mCi) of the radiopharmaceutical were obtained with the SPECT (Single Photon Emission Computed Tomography) tomography. Samples from regions of interest (ROI) were used for the kinetic study applying the kinetic proposed model. The first phase of the study (activity 370 MBq) was aimed to evaluate the kinetic parameters. Subsequently, the patient underwent the [177Lu-DOTA0,Tyr3 ]OCTREOTATE radiotherapy protocol, under the physician\'s prescription (up to four cycles of 7.4 GBq (200 mCi)). Thus, it was possible to previously estimate the kinetic constants ki,j relative to biodistribution of [177Lu-DOTA0,Tyr3 ]OCTREOTATE in the body. The ki,j is the transfer fraction from the ith compartment (a tissue or an organ) to the jth compartment. Only few organs showed significant ROI radioactivity count level, among them: the liver, kidney, blood and carcinoid tumors. The MIRD method and the kinetic constants ki,j were used to estimate the absorbed dose in 26 body organs. The absorbed dose D(mGy/MBq) was comparable to other methods described in the literature. For an adult patient of 73.6 kg, on average, the kidneys (without amino acid protectors) showed the highest dose (2.39 mGy/MBq) followed by liver (0.70 mGy / MBq) and tumor (0.52 mGy/MBq) with a tissue size of approximately 100 g. It was observed that tumors receive the same absorbed dose D(mGy/MBq) regardless their position in the body. This finding is due to the predominance of the tissue radiation damage of beta particles compared to gamma radiation that has little yield emission in the 177Lu decay scheme. Therefore, the kinetic parameters ki,j that promote the uptake of 177Lu in cells are primarily responsible for the absorbed D dose in the tumor and other organs.
APA, Harvard, Vancouver, ISO, and other styles
4

Filho, José de Souza Caldeira. "Síntese, análise, purificação e biodistribuição em modelo animal do Radiofármaco 177Lu3+-dotatato para uso diagnóstico e terapêutico em tumores neuroendócrinos." Universidade de São Paulo, 2009. http://www.teses.usp.br/teses/disponiveis/85/85131/tde-02062009-160531/.

Full text
Abstract:
Este trabalho teve por objetivo propor uma racionalização da síntese, da análise e da purificação do radiofármaco 177Lu3+-DOTATATO para uso diagnóstico e terapêutico em tumores neuroendócrinos, bem como avaliar a biodistribuição deste radiofármaco em modelo animal. A reação de complexação para a síntese do radiofármaco foi realizada em tampão acetato de amônio 0,5 M, pH 7,0, à 95 oC, com tempo de reação de 30 minutos. Obteve-se pureza radioquímica > 95%, de acordo com a análise por cromatografia em ITLC-SG, utilizando-se como fase móvel, tampão citrato de sódio 0,1 M, pH 5,0. A razão molar-limite 177Lu3+: DOTATATO utilizada na síntese do radiofármaco 177Lu3+-DOTATATO foi dependente da atividade específica e da procedência do radioisótopo, sendo de 1:3,5 (370 MBq : 2,6 mg) para radioisótopo oriundo do Oak Ridge National Laboratory/EUA e de 1:16 (370 MBq : 11,8 mg) para o radioisótopo oriundo do Nuclear Analytical and Medical Services/Holanda, considerando para ambos, um decaimento de cinco dias a partir da data de produção do radioisótopo. Esta racionalização da síntese do radiofármaco 177Lu3+-DOTATATO permite uma grande economia nos custos de produção. O estudo químico da síntese do radiofármaco também evidenciou a interferência do 177Hf4+, produto de decaimento do 177Lu3+, como competidor do 177Lu3+ pelo DOTATATO. A preparação radiofarmacêutica mostrou-se estável durante 24 horas, a uma atividade de 2775 MBq, com adição de 0,6 mg/mL de ácido gentísico, mantida em gelo seco. Nos estudos de biodistribuição em camundongos Swiss e Nude demonstrou-se a especificidade do radiofármaco pelos tecidos receptor-específicos para somatostatina como pâncreas, estômago, pulmão, adrenais, rins e de células tumorais AR42J. Palavras chave: síntese, complexação, radiofármaco, 177Lu-DOTATATO, tumor neuroendócrino.<br>The aim of this work was to propose rationalization in the synthesis, analysis and purification of radiopharmaceutical 177Lu3+-DOTATATO for diagnostic and therapeutic use in neuroendocrine tumors, as well as for evaluating biodistribution of this radiopharmaceutical in an animal-model. The complexation reaction for the synthesis of radiopharmaceutical was carried out in ammonium acetate buffer 0.5 M, pH 7.0, for 30 minutes at 95 oC. The radiochemical purity was > 95%, according to analysis by chromatography in ITLC-SG, when using the sodium citrate buffer 0,1 M, pH 5.0, as the mobile phase. The molar-limit ratio 177Lu3+: DOTATATO, used in the synthesis of radiopharmaceutical 177Lu3+-DOTATATO, in ammonium acetate buffer 0.5 M, pH 7.0, for 30 minutes at 95 oC, was dependent on the specific activity and origin of the radioisotope, this being 1:3.5 (370 MBq : 2.6 mg) for that from the Oak Ridge National Laboratory/U.S.A., and 1:16 (370 MBq : 11.8 mg) for that from Nuclear Analytical and Medical Services/Holland, when considering a decay of five days from the production date of the radioisotopes. This rationalization in the synthesis of radiopharmaceutical 177Lu3+-DOTATATO permits high economy in production costs. Chemical studies on the synthesis of radiopharmaceuticals also placed in evidence the interference of 177Hf4+, the decay product of 177Lu3+, as the 177Lu3+ competitor for DOTATATO. Radiopharmaceutical preparation proved to be stable during 24 hours, at an activity rate of 2775 MBq, with the addition of 0.6 mg/mL of gentisic acid and when kept in dry ice. In biodistribution studies on Swiss and Nude mice, the specificity of radiopharmaceutical for somatostatin positive-receptor tissues, such as the pancreas, stomach, lungs, adrenal glands, kidneys and the cell tumor AR42J was demonstrated. Key words: synthesis, complexation, radiopharmaceutical, 177Lu3+-DOTATATO, neuroendocrine tumors
APA, Harvard, Vancouver, ISO, and other styles
5

Garske-Román, Ulrike. "177Lu-DOTA-octreotate Radionuclide Therapy of Neuroendocrine Tumours : Dosimetry-Based Therapy Planning and Outcome." Doctoral thesis, Uppsala universitet, Institutionen för medicinska vetenskaper, 2012. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-183417.

Full text
Abstract:
Peptide receptor radionuclide therapy for the internal radiation of neuroendocrine tumours expressing somatostatin receptors has made great advances and offers promising results. 177Lu-DOTA-octreotate is one of the most widely used radiopeptides, but kidneys and bone marrow are organs at risk. Methods of measuring radiation doses to at-risk organs and tumours (dosimetry) on an individual patient basis have been regarded as impracticable and a maximum of 4 treatment cycles has widely been accepted as the treatment standard instead. The first aim of this thesis was to establish a clinically feasible protocol to calculate absorbed doses to bone marrow and the kidneys during therapy with 177Lu-DOTA-octreotate. A new dosimetry protocol for the bone marrow was described. Dosimetry for solid organs had previously been described based on 3-dimensional imaging by the research group. In the current thesis it was demonstrated that in most patients only minor changes of the effective half-life occurred in the kidneys. By performing complete dosimetry during the first cycle and comparing it with the uptake in later cycles, it was shown that the absorbed dose can be cal-culated based on the activity concentration at 24 hours after therapy. The study concluded that 50% of all patients could receive more than the standard 4 treatment cycles with 7.4 GBq 177Lu-DOTA-octreotate without passing the limit of 23 Gray to the kidneys or 2 Gray to the bone marrow, whereas 20% would tolerate fewer than 4 cycles.  The second aim was to describe treatment outcomes of dosimetry-guided therapy with 177Lu-DOTA-octreotate. Patients with metastasized colorectal neuroendocrine tumours and bronchial carcinoids were shown to have longer survival with this method than previously reported. Morphological tumour response could be correlated to time to progression. Furthermore, in a case of low-differentiated neuroendocrine cancer it was shown that large tumours with high proliferation can also be treated with this method and that tumour-to-risk organ ratios can improve in later cycles, resulting in a more effective treatment. Dosimetry-guided, fractionated radionuclide therapy with 177Lu-DOTA-octreotate is a valuable treatment option for patients with advanced neuroendocrine tumours expressing somatostatin receptors.
APA, Harvard, Vancouver, ISO, and other styles
6

Vanezi, Maria [Verfasser]. "Fernmetastasierte neuroendokrine Tumoren des Pankreas: Ansprechen auf Radiopeptidtherapie mit 177Lu-DOTA-Octreotat / Maria Vanezi." Bonn : Universitäts- und Landesbibliothek Bonn, 2020. http://d-nb.info/1218301716/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Reinhardt, Svenja [Verfasser], and Andrei [Akademischer Betreuer] Todica. "Nebenwirkungen und Ansprechen nach einer Radioligandentherapie mit 177Lu-DKFZ-PSMA-617 / Svenja Reinhardt ; Betreuer: Andrei Todica." München : Universitätsbibliothek der Ludwig-Maximilians-Universität, 2020. http://d-nb.info/1222909065/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Nava, Cabrera Miguel Angel. "Cálculo dosimétrico del 177Lu-iPSMA y 225Ac-iPSMA a nivel celular en un modelo de metástasis ósea." Tesis de maestría, Universidad Autónoma del Estado de México, 2020. http://hdl.handle.net/20.500.11799/109770.

Full text
Abstract:
En esta tesis se realizó un modelo de metástasis ósea derivada de células de cáncer de próstata en un modelo murino con el propósito calcular la dosis absorbida en el núcleo de las células de cáncer de próstata considerando la biocinética del 177Lu-iPSMA y el 225Ac-iPSMA en el modelo in vivo de metástasis ósea. Para apoyar este cálculo se obtuvieron las fracciones de energía depositadas para cada radiofármaco utilizando simulación Monte Carlo<br>Las metástasis óseas derivadas de cáncer de próstata, además de su gran incidencia, generan gran cantidad de sintomatología adversa. El tratamiento mediante radiofármacos de tercera generación como 177Lu-iPSMA, ha permitido una mayor expectativa de vida. No obstante, la remisión completa sigue siendo deficiente y en algunos casos la enfermedad progresa a pesar de varios ciclos de terapia. Como alternativa, se comenzó a utilizar el 223RaCl2, un emisor α con capacidad para eliminar metástasis, pero con la desventaja de generar toxicidad en otros tejidos. Recientemente, se sugirió emplear inhibidores de PSMA marcados con el emisor α 225Ac, los cuales han mostrado alto potencial para destruir células tumorales de manera selectiva, minimizando el daño a tejidos y órganos sanos. En trabajos previos se ha mostrado clínicamente la eficiencia de estos radiofármacos para tratar metástasis óseas, pero no se ha realizado la dosimetría a nivel celular. Por lo tanto, el objetivo de este trabajo fue calcular la dosis absorbida de 177Lu-iPSMA y 225Ac-iPSMA en un modelo de metástasis ósea y comparar la eficiencia entre ambos mediante la razón de dosis entregada al tumor por cada uno. La metástasis intraósea, se indujo en ratones macho CD1 de ocho semanas de edad, mediante la inoculación de células LNCaP a través de la articulación femurotibial. La metástasis se desarrolló en seis semanas. Los huesos con presencia de metástasis fueron extraídos y analizados mediante cortes histológicos. La fracción de actividad depositada por los radiofármacos 177Lu-iPSMA y 225Ac-iPSMA en el núcleo de las células metastásicas se determinó con el kit de extracción nuclear (2900, Merck Millipore, USA), el cual permitió separar los compartimentos celulares para poder medir la actividad en cada uno de éstos. Los factores de dosis de ambos radionúclidos para calcular la dosis absorbida en el núcleo de las células, se determinaron con el código MCNPX5. Posteriormente, se evaluó la biodistribución de ambos radiofármacos en 5 tiempos distintos: el tiempo cero (después de la administración del radiofármaco), 4, 48, 96 y 192 horas. Con los datos de la biodistribución y con ayuda del software OLINDA se obtuvieron los modelos biocinéticos de ambos radiofármacos y con éstos se logró determinar el número de desintegraciones en unidades de MBqh. Con la información obtenida se calculó la dosis absorbida en el núcleo de las células metastásicas de cáncer de próstata debida a ambos radiofármacos y se comparó la eficiencia de ambos a partir de este valor. Se obtuvo que para el tumor la razón de dosis entre el 225Ac-iPSMA y el 177Lu-iPSMA fue aproximadamente de 5, siendo de 2.3 Gy para el primero y de 0.5 Gy para el segundo, ambos por unidad de MBq inyectado.<br>Consejo Nacional de Ciencia y Tecnología Universidad Autónoma del Estado de México
APA, Harvard, Vancouver, ISO, and other styles
9

CARRILLO, CAZARES ANDRES 732305, and CAZARES ANDRES CARRILLO. "Evaluación teórica-experimental del cambio de temperatura en tejido por efecto fototérmico plasmónico del sistema 177Lu-AuNP-RGD." Tesis de maestría, Universidad Autónoma del Estado de México, 2017. http://hdl.handle.net/20.500.11799/68705.

Full text
Abstract:
The working group of National Laboratory of Research and Development of Radiopharmaceuticals (LANIDER) from ININ has developed radiopharmaceuticals for diagnosis and therapy at last for the last 20 years. Recently it developed a radiopharmaceutical based on gold nanoparticles (AuNPs) functionalized with the peptide sequence Arg-Gly-Asp (RGD). The RGD sequence has shown a high affinity for avB3 integrins over-expressed in various cancer cells. When AuNPs are exposed to electromagnetic radiation as laser light, the surface plasmon resonance (SPR) effect is induced, in which the free electrons absorb and disperse to light. These processes are described by Mie theory, which determines the probability of the process by its effective sections Cabs and Csca and considers the sum of these as effective extinction section Cext. Cabs is directly related to the heat production generated by the AuNP (with a temperature range of -+ 800 C) and has been shown to cause irreversible thermal cell destruction due to uncontrolled temperature increase, a process called Plasma Photothermal Therapy. Therefore, the overall objective of this project was to theoretically evaluate the change in tissue temperature by the presence of the AuNP-RGD conjugate when irradiated with laser light using a heat diffusion model that considers the absorption, dispersion and extinction coefficients of the system. Likewise, the theoretical value was correlated with the experimental value obtained when irradiating the system with laser light of 532 nm. The development of this project was planned in two phases, one theoretical and one experimental. In the first, Cabs , Csca and Cext were determined by Mie theory, considering the AuNP-RGD in water and tissue (Liver and Colon). In the second, samples of AuNP-RGD were irradiated in water and tissue with a pulsed Nd: YAG laser at a wavelength of 532nm and variable repetition frequencies (5, 10 and 15 Hz) and temperature was monitored every second using a thermocouple, temperature vs time graphs were constructed and a model of temperature distribution was proposed between the theoretical and experimental data. From Mie theory it was determined that Cext obtained at 532nm for different samples does not represent the maximum value, otherwise, for AuNP-RGD in water, colon and liver are respectively 94%, 98% and 96% of their maximum value obtained at 522.5 nm and 525 nm. From experimental part, it was determined that temperature increase at macroscopic level is about 13 C with a concentration of 6.54x1011 AuNP /mL after an irradiation of 200s at a 10Hz frequency and after 90s at 15 Hz frequency. Using temperature vs time curves a temperature model was constructed based on theoretical values of Cabs and a mass loss correction factor describing the behavior at the macroscopic level of the system. As a conclusion of this project, we have that calculations of Cabs , Csca and Cext for (AuNP-RGD)-water, (AuNP-RGD)-colon and (AuNP-RGD)-liver help to understand temperature increase observed when they are irradiated with laser light at 532 nm. Observed temperature increase was approximately 13 °C which is sufficient to produce cell death by plasmonic photothermal therapy.<br>El grupo de trabajo del Laboratorio Nacional de Investigación y Desarrollo de Radiofármacos (LANIDER) del ININ desarrolla desde hace más de 20 años radiofármacos para diagnóstico y terapia. Recientemente desarrolló uno basado en nanopartículas de oro (AuNPs) funcionalizadas con la secuencia peptídica Arg-Gly-Asp (RGD). La secuencia RGD ha mostrado una gran afinidad por las integrinas avB3 sobre expresadas en diversas células de cáncer. Cuando las AuNPs se exponen a radiación electromagnética como luz láser, se induce el efecto de resonancia de plasmón de superficie (SPR), en este, los electrones libres absorben y dispersan a la luz. Estos procesos son descritos por la teoría de Mie, la cual determina la probabilidad del proceso mediante sus secciones eficaces Cabs y Csca, y considera a la suma de éstas como la sección eficaz de extinción Cext. La 𝐶𝑎𝑏𝑠 está directamente relacionada con la producción de calor que genera la AuNP (con un alcance de temperatura de +- 800 grados centigrados ) y se ha demostrado que causa destrucción celular térmica irreversible por el aumento incontrolado de temperatura, proceso denominado Terapia Fototérmica Plasmónica. Por lo anterior, el objetivo general de este proyecto fue evaluar teóricamente el cambio de temperatura en tejido por la presencia del conjugado AuNP-RGD al ser irradiado con luz láser mediante un modelo de difusión de calor que considera los coeficientes de absorción, dispersión y extinción del sistema. De igual manera, el valor teórico se correlacionó con el valor experimental obtenido al irradiar dicho sistema con luz láser de 532 nm. El desarrollo de este proyecto se planteó en dos fases, una teórica y una experimental. En la primera, se determinaron los Cabs , Csca y Cext mediante teoría Mie, considerando a las AuNP-RGD en agua y tejido (hígado y colon). En la segunda se irradiaron muestras de AuNP-RGD en agua y tejido con un láser pulsado de Nd:YAG a una longitud de onda de 532 nm y frecuencias de repetición variables (5, 10 y 15 Hz) y se monitoreó la temperatura cada segundo usando un termopar, se construyeron las gráficas de temperatura vs tiempo y se planteó un modelo de distribución de temperatura ente los datos teóricos y los experimentales. De la teoría Mie se determinó que el Cext obtenido a 532 nm para las diferentes muestras no representa el valor máximo, sino, el 94%, 98% y 96% de su valor máximo para AuNP-RGD en agua, colon e hígado respectivamente, obtenidos a 522.5 nm y 525 nm. En la parte experimental se determinó que el incremento de temperatura a nivel macroscópico después de una irradiación de 200 s a una frecuencia de 10 Hz ó 90 s a una frecuencia de 15 Hz es alrededor de 13°C para una concentración de 6.54x1011AuNP/mL. A partir de las curvas de temperatura vs tiempo se construyó un modelo de una temperatura basado en los valores teóricos de Cabs y un factor de corrección por pérdida de masa que describe el comportamiento a nivel macroscópico del sistema. Como conclusión de este proyecto tenemos que los cálculos de los Cabs, Csca y Cext para (AuNP-RGD)-agua, (AuNP-RGD)-colon y (AuNP-RGD)-hígado ayudan a entender el incremento de temperatura observado cuando son irradiados con luz láser de 532 nm. El incremento de temperatura fue suficiente para producir muerte celular por terapia Fototérmica Plasmónica.<br>CATEDRÁS-CONACyT-ININ-337 CONACYT-SEP-CB-2014-01-242443.
APA, Harvard, Vancouver, ISO, and other styles
10

Sánchez, García María de Fátima, and García Blanca Eli Ocampo. "Diseño y optimización del proceso de producción del Radiofármaco 177Lu-DOTA-Nal3-Octreotido para el tratamiento de Tumores Gastroenteropancreáticos." Tesis de Licenciatura, Medicina-Quimica, 2013. http://ri.uaemex.mx/handle/20.500.11799/13886.

Full text
Abstract:
Diseño y optimización del proceso de producción del Radiofármaco 177Lu-DOTA-Nal3-Octreotido para el tratamiento de Tumores Gastroenteropancreáticos, es un trabajo realizado por el autor: Sánchez García, María de Fátima, Ocampo García, Blanca Eli; con fecha de publicación del año 2013 y con apoyo de edición de Medicina-Quimica
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "177Lu"

1

Iowa State University Research Foundation Staff. Chemistry 167L, 177L, 178L. 4th ed. Kendall/Hunt Publishing Company, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Iowa State University Research Foundation Staff. Chemistry 167L, 177L, 178L. 3rd ed. Kendall/Hunt Publishing Company, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Iowa State University Research Foundation Staff. Chemistry 167L, 177L, 178L. 2nd ed. Kendall/Hunt Publishing Company, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Iowa State University Research Foundation Staff. Laboratory Studies of Chemical Systems-Chemistry, 167L, 177L, 178L. Kendall/Hunt Publishing Company, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "177Lu"

1

Wild, Damian. "Theranostics with Somatostatin Receptor Antagonists." In Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum. Springer International Publishing, 2024. http://dx.doi.org/10.1007/978-3-031-33533-4_35.

Full text
Abstract:
AbstractSomatostatin receptors (SST), especially SST subtype 2 (SST2), are important targets for the management of patients with neuroendocrine tumours (NETs) or neuroendocrine neoplasias (NENs). Peptide receptor radionuclide therapy (PRRT) with 177Lu-labelled SST agonists, for example, 177Lu-DOTA-TOC or 177Lu-DOTA-TATE, is recommended by the European Neuroendocrine Tumour Society as second-line treatment after progression under treatment with somatostatin analogues in patients with metastatic, SST positive grade 1 and 2 midgut NETs. PET/CT imaging with 68Ga-labelled SST agonists, for example, 68Ga-DOTA-TOC or 68Ga-DOTA-TATE, plays an important role in staging and restaging NETs. Furthermore, SST PET/CT can identify those patients with highly 68Ga-DOTA-TOC or 68Ga-DOTA-TATE avid tumours. These are the patients who will benefit from PRRT. As a result, SST PET/CT can predict the treatment efficacy of 177Lu-DOTA-TOC or 177Lu-DOTA-TATE. This allows a personalized treatment approach, also called a therapeutic/diagnostic approach = theranostic approach. Until recently, it was thought that internalisation of the radiolabelled agonist was mandatory for SST-mediated imaging and therapy. It was Ginj et al. who proposed in 2006 the paradigm shift that radiolabelled SST antagonists may perform better than agonists despite lacking internalisation. In this chapter, the preclinical and clinical development, current status and possible future developments of radiolabelled SST antagonists are discussed.
APA, Harvard, Vancouver, ISO, and other styles
2

Turner, J. Harvey. "Evaluation of Real-World Efficiency of 177Lu-PSMA Radioligand Therapy of Metastatic Prostate Cancer." In Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum. Springer International Publishing, 2024. http://dx.doi.org/10.1007/978-3-031-33533-4_33.

Full text
Abstract:
AbstractThroughout the world, hundreds of patients with advanced metastatic prostate cancer are currently being treated with 177Lu-PSMA radioligands on compassionate usage protocols in accord with published guidelines of the European Association of Nuclear Medicine (EANM). However, 7 years after the introduction of 68Ga/177Lu-PSMA theranostic management of metastatic castration-resistant prostate cancer (mCRPC), it remained unapproved by any national regulatory authority, and has yet to achieve oncologist/urologist acceptance into mainstream clinical practice. The reasons for the nonacceptance of 177Lu-PSMA-radioligand therapy (RLT) are explored in this review, which charts the evolution of this very promising treatment modality, pioneered in German, Austrian, and Australian academic hospitals, from which many retrospective reports of efficacy have been published. This efficacy has subsequently been demonstrated by completion of the Pharma randomized controlled trial, the VISION Study which led to formal regulatory approval. However, in order to promote worldwide availability, and to evaluate efficiency in respect of improved survival and quality of life, the proposed WARMTH NIGHTCAP (World Association for Radiopharmaceutical and Molecular Therapy National Investigators Global Harmonised Theranostics of Cancer of Prostate) Study was designed to prospectively audit 68Ga/177Lu-PSMA RLT in a large real-world population of mCRPC patients, in up to 50 countries, now being treated on compassionate access programs. The NIGHTCAP Study did not come to fruition due to the COVID pandemic but the design principles remain valid.
APA, Harvard, Vancouver, ISO, and other styles
3

Schuchardt, Christiane, Harshad R. Kulkarni, Vikas Prasad, Carolin Zachert, Dirk Müller, and Richard P. Baum. "The Bad Berka Dose Protocol: Comparative Results of Dosimetry in Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE, 177Lu-DOTANOC, and 177Lu-DOTATOC." In Recent Results in Cancer Research. Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-27994-2_30.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Zhu, Hua, Xiaoyi Guo, Xiangxi Meng, and Zhi Yang. "Is It Possible to Target HER2 Using Affibody Receptor Radionuclide Therapy?" In Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum. Springer International Publishing, 2024. http://dx.doi.org/10.1007/978-3-031-33533-4_38.

Full text
Abstract:
AbstractHuman epidermal receptor type 2 (HER2; also known as ErbB2) is an idea target for target therapy. HER2-targeted treatments with trastuzumab and its derivates or analogues can improve the overall survival of patients with HER2-overexpression tumors. This chapter describes the construction and clinical translational study of 64Cu-NOTA-Trastuzumab, 124I-Trastuzumab, and 68Ga-HER2 affibody tracer. Inspired by recently most popular peptide receptor radionuclide therapy with lutetium-177 dotatate (177Lu-DOTATATE) for advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and 177Lu-PSMA-617 for metastatic castration resistant prostate cancer therapy (mCRPC), the establishment of affibody receptor radionuclide therapy (ARRT) has the potential to provide an alternative treatment option for future HER2 positive resistant patients.
APA, Harvard, Vancouver, ISO, and other styles
5

Jadvar, Hossein. "Precision Oncology with PSMA-Targeted α-Particle Therapy of mCRPC." In Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum. Springer International Publishing, 2024. http://dx.doi.org/10.1007/978-3-031-33533-4_15.

Full text
Abstract:
AbstractProstate-specific membrane antigen (PSMA) has been firmly established as a clinically relevant biomarker in imaging and targeted radionuclide therapy (theranostics) of prostate cancer, particularly in the metastatic castrate-resistant state. Numerous investigations from around the world in both academic and pharma settings are focused on research and development of safe and effective PSMA-based theranostic agents. Encouraging results from retrospective studies using the β-particle emitting 177Lu-PSMA-617 radioligand therapy prompted prospective phase II and phase III randomized clinical trials with recently published favorable results of the VISION trial. While these pivotal investigations continue, there has also been major growing interest in the potential clinical utility of α-particle PSMA-targeted therapeutic agents. After a brief review of PSMA biology, imaging with positron emission tomography, and current experience with targeted β-particle (177Lu) therapy, this article summarizes the preclinical and early clinical studies that have evaluated the PSMA-targeted agents conjugated properly to α-particle radiolabels including 225Ac, 213Bi, 227Th, 212Pb, and 149Tb.
APA, Harvard, Vancouver, ISO, and other styles
6

Jiang, Lei, and Zhen Cheng. "177Lu-Labeled RGD-BBN Peptide for Targeting Prostate Cancer." In Methods in Pharmacology and Toxicology. Springer New York, 2015. http://dx.doi.org/10.1007/7653_2015_50.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Burger, Irene A., and Thomas A. Hope. "Advances in Molecular Imaging and Therapy and Its Impact in Oncologic Imaging." In IDKD Springer Series. Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-27355-1_3.

Full text
Abstract:
AbstractThe theranostic concept to use diagnostic and therapeutic nuclides to image and treat cancer was established many years ago for thyroid disease. With the success of [177Lu]-labeled therapeutic agents targeting neuroendocrine tumors or prostate cancer, the interest for this concept has been significantly rising. The possibility to localize and quantify a therapeutic target within the patient opens up novel possibilities, but also challenges for patient selection, dosimetry, and response assessment. Especially for response assessment we however, still rely on the morphologic changes. With the increasing use of immunotherapy and other biological approaches, image interpretation needs a profound understanding of the therapeutic mechanism and impact on imaging parameters for accurate assessment of tumor response and guidance for appropriate therapy selection.
APA, Harvard, Vancouver, ISO, and other styles
8

Harris, P., R. Henkelmann, S. Marx, and K. Zhernosekov. "The Evolution of n.c.a. 177Lu to n.c.a. 177Lu-Edotreotide for the Treatment of Neuroendocrine Tumours. Sixteen Years of Collaboration Between Zentralklinik Bad Berka and ITM." In Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum. Springer International Publishing, 2024. http://dx.doi.org/10.1007/978-3-031-33533-4_13.

Full text
Abstract:
AbstractDiagnostic and therapeutic radionuclides offer an excellent platform for the development of innovative drugs, which enable non-invasive visualization of diseases and complementary targeted treatments. The concept of personalized medicine is realized! This innovation in nuclear medicine together with an increasing demand for high-quality radionuclides and radiopharmaceuticals has triggered the expansion of nuclear medicine as a hospital speciality, together with the development of a new radiotheranostics industry.
APA, Harvard, Vancouver, ISO, and other styles
9

Müller, Cristina, and Nicholas P. van der Meulen. "Terbium “Sisters”: More Than just a “Swiss Army Knife”." In Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum. Springer International Publishing, 2024. http://dx.doi.org/10.1007/978-3-031-33533-4_23.

Full text
Abstract:
AbstractThe concept of radiotheragnotics is employed at many nuclear medicine entities worldwide, where 68Ga and 177Lu are the most commonly used radiometals for PET imaging and radionuclide therapy, respectively.The application of radionuclides of the same element (i.e., radioisotopes) would enable the preparation of chemically identical radiopharmaceuticals for both imaging and therapy. At the Paul Scherrer Institute, the realization of this concept has been a major research focus over the last decade. Among several interesting metals, terbium is of particular relevance. It comprises four radioisotopes suitable for nuclear medicine purposes, including imaging using single photon emission computed tomography (SPECT; terbium-155) and positron emission tomography (PET; terbium-152), respectively, as well as targeted radionuclide therapy using α-particles (terbium-149) and β¯-particles (terbium-161).This chapter presents the birth of the terbium “sisters” at PSI and briefly summarizes the most important achievements obtained with each of the four sisters. Future perspectives and challenges with regard to clinical translation of the “terbium sister concept” are presented and discussed.
APA, Harvard, Vancouver, ISO, and other styles
10

Rasaneh, S., H. Rajabi, M. H. Babaei, et al. "The evaluation of therapeutic effect of trastuzumab labeled 177lu in breast cancer cell line." In IFMBE Proceedings. Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-642-03474-9_262.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "177Lu"

1

Miller, C. M., R. Engleman, and R. A. Keller. "Resonance ionization mass spectrometry for high-resolution mass-resolved spectra of rare isotopes." In OSA Annual Meeting. Optica Publishing Group, 1985. http://dx.doi.org/10.1364/oam.1985.tha2.

Full text
Abstract:
Previous isotope ratio measurements using resonance ionization mass spectrometry (RIMS) have used element selective photoionization with isotope ratios measured by dispersion of ions in a mass spectrometer. To increase the accuracy and dynamic range of isotope ratio measurements, it may be necessary to use isotopically selective ionization. To be successful in this task it is necessary to know isotope shifts and hyperfine structures of the optical transition(s) used for the isotopes of interest. We are particularly interested in rare and sometimes highly radioactive elements for which this information is not readily available. We demonstrate that the sensitivity and mass selectivity of the RIMS technique itself can be used to obtain the needed spectra. With this goal in mind, RIMS was used to acquire high-resolution optical spectra of rare isotopes. To demonstrate the potential of this technique, hyperfine spectra of the 2 D 3 / 2 0 ← 2 D 3 / 2 lutetium transition at 22,125 cm–1 are presented for 176Lu, 175Lu, 174Lu, and 173Lu. The latter two are rare isotopes with half-lives of 3.3 and 1.4 yr whose optical spectroscopy has not previously been explored. Sensitivity is documented by the fact that the total amount of these rare isotopes in our sample was 2 × 10–10 g and 3 × 10–11 g. Analysis of the spectra confirms that the spin of 174Lu is unity and yields values for the hyperfine constants and isotope shifts of these nuclei.
APA, Harvard, Vancouver, ISO, and other styles
2

Suman, Sonam, Rahul V. Parghane, and Sandip Basu. "177Lu-PSMA-617 PRLT versus Combined 177Lu-PSMA-617 and Abiraterone Therapy in mCRPC: A Comparative Evaluation Study." In 6th International Conference on Radiopharmaceutical Therapy (ICRT 2021) Abstracts. Thieme Medical and Scientific Publishers Pvt. Ltd., 2022. http://dx.doi.org/10.1055/s-0042-1748672.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Nyakale, Nozipho, Shona Badhree, Lerwine Harry, Venesen Pillay, and Mike Sathekge. "177Lu PSMA as Salvage Therapy for Hepatocellular carcinoma." In Abstracts for the 18th International Conference on Radiopharmaceutical Therapy (ICRT). Thieme Medical and Scientific Publishers Pvt. Ltd., 2023. http://dx.doi.org/10.1055/s-0043-1769977.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Dooper, Marten. "177Lu-PSMA effective both in mCRPC and mHSPC." In ESMO Congress 2024, edited by Stefan Rauh. Medicom Medical Publishers, 2024. http://dx.doi.org/10.55788/8b938814.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Dracoulis, G. D. "Structure Of Multi-Quasiparticle Isomers In The Region Of 177Lu." In NUCLEI AT THE LIMITS. AIP, 2005. http://dx.doi.org/10.1063/1.1905283.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Khandaker, Mayeen Uddin, Hiromitsu Haba, and Hasan Abu Kassim. "Production of 177Lu, a potential radionuclide for diagnostic and therapeutic applications." In NATIONAL PHYSICS CONFERENCE 2014 (PERFIK 2014). AIP Publishing LLC, 2015. http://dx.doi.org/10.1063/1.4915229.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Mader, N., T. Weight, K. Klimek, et al. "Clinical Evaluation of Salivary Gland-Function after 177Lu-PSMA Radioligand Therapy." In 61. Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin. Georg Thieme Verlag, 2023. http://dx.doi.org/10.1055/s-0043-1766319.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Plotkin, M., D. Beltsevich, M. Michel, et al. "Treatment of progressive metastatic pheochromocytomas and paragangliomas with 177Lu-DOTATATE PRRT." In NuklearMedizin 2021 – digital. Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0041-1727073.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Jadidan, A., M. Z. Anwari, A. Riana, Y. W. Sari, and D. Hardiansyah. "Biodistribution study of lutetium hydroxyapatite (177Lu-HA) for liver cancer therapy." In PROCEEDINGS OF THE INTERNATIONAL CONFERENCE AND SCHOOL ON PHYSICS IN MEDICINE AND BIOSYSTEM (ICSPMB): Physics Contribution in Medicine and Biomedical Applications. AIP Publishing, 2021. http://dx.doi.org/10.1063/5.0047910.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

van den Heuvel, Robert. "NETTER-2: Practice-changing results for 177Lu-DOTATATE in GEP-NETs." In ASCO Gastrointestinal Cancers Symposium, edited by Rachel Giles. Medicom Medical Publishers, 2024. http://dx.doi.org/10.55788/045465ef.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "177Lu"

1

Hertelendi, Marianna, Oulaya Belguenani, Azzeddine Cherfi, Ilya Folitar, Gabor Kollar, and Berna Degirmenci Polack. Protocol for a systematic literature review of efficacy and safety of [177Lu]Lu-DOTA-TATE in adults with inoperable or metastatic somatostatin receptor-positive pheochromocytomas/paragangliomas, bronchial and unknown origin neuroendocrine tumors, and medullary thyroid carcinoma. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2023. http://dx.doi.org/10.37766/inplasy2023.3.0030.

Full text
Abstract:
Review question / Objective: The aim of this systematic review is to identify and summarize the use of [177Lu]Lu-DOTA-TATE as a treatment for neuroendocrine tumors (NETs) of non-gastroenteropancreatic (GEP) origin to understand evolving clinical practice. Condition being studied: Adults (as defined by the authors) with any of the following inoperable or metastatic SSTR-positive NETs: PPGL, thymic NET, bronchial NET, NET of unknown primary origin, or MTC. Efficacy and safety outcomes were analyzed. Eligibility criteria: Search included studies published up to May 13, 2021. No geographic, language, or age restrictions were applied in the search, but only English-language publications reporting studies in adults were selected for inclusion. Studies that included multiple NET types were only included if the results and baseline characteristics were provided for individual NETs. Studies that included both pediatric and adult patients were retained, if it was possible to extract data for adults only.
APA, Harvard, Vancouver, ISO, and other styles
2

Vallabhajosula, Shankar. Radioimmunotherapy (RIT) Dose-Escalation Studies in Prostate Cancer Using Anti-PSMA Antibody 177Lu-J591: RIT Alone and RIT in Combination with Docetaxel. Defense Technical Information Center, 2008. http://dx.doi.org/10.21236/ada512754.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Vallabhajosula, Shankar. Radioimmunotherapy (RIT) Dose-Escalation Studies in Prostate Cancer Using Anti-PSMA Antibody 177Lu-J591: RIT Alone and RIT in Combination with Docetaxel. Defense Technical Information Center, 2009. http://dx.doi.org/10.21236/ada518243.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Tagawa, Scott T. A Randomized Phase 2 Trial of 177Lu Radiolabeled Anti-PSMA Monoclonal Antibody J591in Patients with High-Risk Castrate, Biochemically Relapsed Prostate Cancer. Defense Technical Information Center, 2012. http://dx.doi.org/10.21236/ada566933.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Vallabhajosula, Shankar. Radioimmunotherapy (RIT) Dose-Escalation Studies in Prostate Cancer Using Anti-PSMA Antibody 177Lu-J591: RIT Alone and RIT in Combination With Docetaxel. Defense Technical Information Center, 2006. http://dx.doi.org/10.21236/ada477232.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Vallabhajosula, Shankar. Radioimmunotherapy (RIT) Dose-Escalation Studies in Prostate Cancer Using Anti-PSMA Antibody 177Lu-J591: RIT Alone and RIT in Combination with Docetaxel. Defense Technical Information Center, 2007. http://dx.doi.org/10.21236/ada477470.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Tagawa, Scott T. A Randomized Phase 2 Trial of 177Lu Radiolabeled Anti-PSMA Monoclonal Antibody J591 in Patients with High-Risk Castrate Biochemically Relapsed Prostate Cancer. Defense Technical Information Center, 2011. http://dx.doi.org/10.21236/ada553447.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Tagawa, Scott T. A Randomized Phase 2 Trial of 177Lu Radiolabeled Anti-PSMA Monoclonal Antibody J591 in Patients with High-Risk Castrate, Biochemically Relapsed Prostate Cancer. Defense Technical Information Center, 2014. http://dx.doi.org/10.21236/ada621020.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Tagawa, Scott T. A Randomized Phase 2 Trial of 177Lu Radiolabeled Anti-PSMA Monoclonal Antibody J591 in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer. Defense Technical Information Center, 2015. http://dx.doi.org/10.21236/ada623383.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Tagawa, Scott T. A Randomized Phase 2 Trial of 177Lu Radiolabeled Anti-PSMA Biochemically Monoclonal Antibody J591 in Patients with High-Risk Castrate, Biochemically Relapsed Prostate Cancer. Defense Technical Information Center, 2010. http://dx.doi.org/10.21236/ada534816.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic '177Lu' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography